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Introduction: Intermittent claudication (IC) is a common and debilitating symptom of 
peripheral arterial disease and is associated with a significant reduction in a sufferer’s 
quality of life.  Guidelines recommend a supervised exercise programme (SEP) as the 
primary treatment option; however, anecdotally there is a low participation rate for 
exercise in this group of patients. We undertook a systematic review of the uptake and 
adherence rates to supervised exercise programmes for individuals with IC. 
Methods: The Medline, Embase and PubMed databases were searched up to January 2015 
for terms related to supervised exercise in peripheral arterial disease. The review had three 
aims: firstly to establish the rates of uptake to SEPs, secondly the rates of adherence to 
programmes and finally to determine the reasons reported for poor uptake and adherence.  
Separate inclusion/exclusion criteria were applied in selecting reports for each aim of the 
review. 
Results: Only 23 of the 53 potentially eligible papers for uptake analysis identified on 
literature searches reported any details of screened patients (n = 7517) with only 24.2% of 
patients subsequently recruited to SEPs. Forty-five percent of screen failures had no reason 
for exclusion reported. 67 papers with 4012 patients were included for analysis of SEP 
adherence. Overall 75.1% of patients reportedly completed a SEP, however only one paper 
defined a minimal attendance required for SEP completion. 54.1% of incomplete adherence 
was due to patient withdrawal and no reason for incomplete adherence was reported for 
16% of cases. 
Discussion: Reporting of SEP trials was poor with regard the numbers of subjects screened 
and reasons for exclusions. Only approximately 1 in 3 screened IC patients was suitable for 
and willing to undertake SEP. Levels of adherence to SEPs and definitions of satisfactory 
adherence were also lacking in the majority of the current literature. Current clinical 
guidelines based upon this evidence base may not be applicable to the majority of IC 
patients and changes to SEPs may be needed to encourage/retain participants. 
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Introduction 
Intermittent claudication (IC) is the most common symptom of peripheral arterial disease 
(PAD), affecting 5 % of the population over the age of 50 years 1 and 20 % of the population 
over 70 years 2. IC is due to muscle ischemia precipitated by exercise and is frequently 
associated with a reduction in walking capabilities 3. Supervised exercise programmes (SEPs) 
for patients with claudication have been demonstrated to improve walking distances and be 
cost effective 4. Current clinical guidelines recommend that all patients with IC are enrolled 
on a group-based SEP 5, 6. Furthermore, centres should consider a programme comprised of 
intermittent walking to near maximal or maximal pain, three times a week, for a minimum 
of 12 weeks 7. 
Although it is agreed that supervised exercise should be the first line treatment, there is 
evidence suggesting that relatively few patients are suitable for and will agree to 
participation in an SEP8.Many who commence an SEP fail to complete the programme of 
classes. Clearly the clinical and cost effectiveness of SEPs for managing the population of IC 
patients as a whole may be significantly affected by poor recruitment and adherence to 
programmes.  
This review has 3 aims, firstly to establish from the existing literature the levels of uptake of 
SEPs in published trials, which we defined as the proportion of screened patients who went 
on to commence an SEP. Secondly to determine patient adherence to SEPs, which was 
defined as the proportion of patients who commenced an SEP and subsequently completed 
all sessions. Thirdly to explore what reasons were reported for lack of uptake or adherence 
in IC patients.   
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Methods 
A systematic review of randomised and non-randomised clinical trials (RCTs) including a SEP 
arm was performed. The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines were used for reporting of  search results9. 
Search Strategy 
Systematic review was performed using Medline, Embase and CENTRAL.  The search 
strategy aimed to include any trials which included SEP either as the control arm or as the 
primary intervention. Search terms used were: 
‘peripheral arterial disease’ [OR] ‘intermittent claudication’ [OR ‘claudication’ [OR] 
‘ischemia’ [AND], ‘exercise’ [OR] ‘running’ [OR] ‘exercise therapy’ [OR] ‘exercise movement’ 
[OR] ‘training’  [AND] ‘supervised’. 
Searches were limited to run from 1947 to January 2015. The search was limited to full text 
articles relating to adults (over 18 years of age) and published in English.  Abstracts 
identified by the database search were independently interrogated for relevance by two 
reviewers (AH & TC). Citations from the full texts of relevant reports were hand searched for 
other relevant references.  
Inclusion criteria 
Two cohorts of reports were selected from within the search results, firstly to assess data on 
rates of uptake, then data on rates of adherence to SEPs. Both cohorts were then examined 
for reporting of reasons for poor uptake and adherence. For both searches, we included 
randomised and prospective non-randomised studies that investigated the role of SEPs in 
patients diagnosed with Intermittent Claudication (Fontaine II/ Rutherford 1-3).These were 
either diagnosed clinically or by interview/ questionnaire. We included any form of SEP 
regardless of the structure, duration, frequency or intensity of training utilised. Papers were 
only included if they specifically reported the numbers of subjects recruited to, commencing 
and completing the SEP. Any studies including patients who were asymptomatic were 
excluded. 
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Rate of SEP Uptake cohort: 
In an attempt to avoid bias, studies were excluded from this cohort if they included any 
active interventions other than an SEP (e.g. medications/supplements, angioplasty, surgery). 
The rationale for exclusion was so that patients refusing to participate would not have been 
deterred by the possibility of randomisation to any treatment other than the SEP. Data was 
collected to include numbers screened and numbers of patients who were subsequently 
allocated to an SEP and attended at least one session.  
Adherence to SEPs cohort: 
 All Studies involving an SEP arm versus any other comparator arm were included in this 
cohort. Data extraction was then limited to the subjects assigned to the SEP arm(s) with 
regard to rates of SEP adherence. 
 
Data extraction  
Any disagreement as to inclusion of a report between the two assessing investigators 
(AH,TC) was settled by consensus with a third (GS). Data extraction was then performed by 
two investigators (AH, TC) using a standardised data extraction sheet. Data regarding  
research unit and country, target population, numbers of patients initially 
screened/referred for SEP, number of participants enrolled to SEP, reasons for non-
enrolment, number of dropouts prior to completion of SEP, reasons for dropout and 
description of the supervised exercise protocol, (frequency, duration, content) were 
collected. 
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Results 
Search results  
The search yielded a total of 333 reports of which 11 were duplicates. Of the remaining 322, 
67 were appropriate for inclusion in one or both sections of the planned analysis. The 
inclusion/exclusion process is summarised in figure 1. 
Included trials 
Our analysis included 67 trials, all of which utilised some form of SEP in claudicants and 
recorded details of recruited subjects and numbers of those who commenced and 
completed an SEP.  52 reports were from randomised trials and the remainder were 
prospective case control or cohort studies. The total of recruited subjects within the 67 
papers was 5817, with 4094 subjects assigned to a study arm which included a SEP.  SEPs 
differed widely between reports both in duration (varying from 4 weeks to 12 months) and 
in type of exercise undertaken (resistance, aerobic, combination - upper/ lower limb). 
Included studies are summarised in Table 1.  
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Author Year Total 
Recruited 
Assigned 
SEP 
% 
Uptake 
% 
Adherence 
SEP 
Duration 
X Per 
week 
Type 
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(Weeks) 
Allen10 2014 27 27 100 100 12 3 Aerobic 
Andreozzi11 2008 44 44 100 100 6 3 Walking 
Beckitt12 2012 38 27 100 100 12 3 Mixed 
Beckitt12 2012 56 42 100 100 12 3 Mixed 
Bendermacher6 2007 39 39 100 60 52 3 Mixed 
Bo13 2013 50 29 100 100 12 3 Walking 
Bronas14 2011 40 20 100 100 12 3 Mixed 
Cheetham15 2004 59 29 100 100 12 1 Mixed 
CLEVER16 2012 119 51 96 92 26 3 Walking 
Collins17 2005 52 27 100 85 24 3 Walking 
Collins18 2012 146 103 100 94 24 3 Walking 
Crowther19 2009 21 10 100 100 52 3 Walking 
Degischer20 2002 69 38 100 100 12 3 Walking 
Delaney21 2014 35 35 100 77 12 3 Mixed 
Duscha22 2011 78 78 100 35 12 3 Walking 
Fokkenrood23 2015 47 47 100 87 12 3 Mixed 
Frans 2010 101 101 100 71 12 3 Walking 
Gardner24 2012 142 106 100 76 104 3 Walking 
Gardner25 2014 180 60 100 87 12 3 Walking 
Gardner26 2005 77 77 100 83 24 3 Walking 
Gardner27 2001 61 31 90 100 24 3 Walking 
Gelin28 2001 264 73 100 59 24 3 Walking 
Greenhalgh29 2008 144 60 100 82 24 1 Mixed 
Hiatt30 1990 25 14 100 71 12 3 Walking 
Hiatt31 1994 29 19 100 100 12 3 Walking 
OR 
Resistance 
Hiatt32 2011 69 69 100 86 24 3 Walking 
Hobbs33 2007 38 19 84 100 12 2 Walking 
Hodges34 2008 28 14 50 100 12 2 Walking 
Janusek35 2014 85 85 100 79 12 3 Walking 
Jones36 2012 22 12 100 100 12 3 Walking 
Jones37 1996 23 23 100 52 12 2 Walking 
Kakkos38 2005 36 12 100 50 24 3 Walking 
King39 2012 12 12 100 92 12 3 Mixed 
Kruideiner40 2011 70 35 100 77 52 3 Mixed 
Kruideiner41 2009 349 297 92 47 52 3 Mixed 
Leicht42 2011 25 12 100 67 52  
3 
Walking 
Mazari43 2012 178 118 85 93 12 3 Mixed 
Meneses44 2011 34 34 100 88 52 2 Mixed 
Mika45 2005 98 49 100 16 12 3 Walking 
Mika46 2006 60 30 100 90 12 3 Walking 
Mika47 2011 68 34 100 88 12 3 Walking 
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Uptake of supervised exercise 
53 studies met the inclusion criteria for the uptake of an exercise protocol section of the 
review. However, only 23 of the 53 papers gave any details of total numbers of potential 
participants screened for participation. Within these reports 1820 subjects recruited from 
7517 screened (24.2%).  
 
Analysis of recruited patients from all 53 studies, showed 3296 were assigned to study arms 
which included a SEP as an intervention. There was a 98.1% rate of subjects assigned to SEP 
arms commencing SEP intervention following randomisation (3235 of 3296 subjects).  
 
Supervised Exercise adherence 
An additional 14 papers met the criteria for inclusion in the adherence to exercise 
programmes section of the review. These reports included comparator interventions of 
arterial surgery, angioplasty and medical therapies either alone or as adjuvants to SEP.  A 
total of 67 papers were included in this analysis with a total of 5817 recruited subjects.  
Mockford48 2014 51 51 100 96 12 3 Mixed 
Nicolai49 2010 304 202 99 45 12 3 Walking 
Parmenter50 2013 22 15 100 93 24 3 Resistance 
Regensteiner51 1996 29 19 100 79 12 3 Mixed 
Sakamoto52 2009 118 118 100 54 52 3 Walking 
Savage53 2001 21 21 52 100 12 3 Walking 
Schlager54 2011 40 20 100 100 24 2 Walking 
Slordahl55 2005 16 16 100 100 8 3 Aerobic 
Spronk56 2010 151 75 100 96 24 2 Walking 
Stewart57 2008 60 30 100 91 24 2 Mixed 
Tew58 2009 57 29 100 93 12 2 aerobic 
Treat-Jacobson59 2009 62 37 100 78 12 3 Walking 
Tsai60 2002 64 32 100 85 12 3 Walking 
Van Pul61 2012 775 775 100 59 24 3 Walking 
Versluis62 2013 10 10 100 100 12 2 / 3 Walking 
Walker63 2000 52 52 100 92 6 2 Mixed 
Wang64 2007 22 17 77 100 12 3 Walking 
Wang65 2008 27 14 100 100 12 3 Walking 
Wang66 2010 10 10 100 100 8 3 Strength 
Zweirska67 2005 104 71 100 87 24 2 Aerobic 
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Any patient assigned to any arm which required SEP was included in the assessment of 
adherence to programmes. Of the 4012 subjects who commenced an SEP in the included 
trials, 3015 were reported as having adequately completed the exercise programme for 
inclusion in the analysis (75.1%). No paper gave a clear definition of the number of sessions 
attended that was considered the minimum for a subject to have completed the SEP 
intervention. 
 
Eight reports included specific comments regarding levels of adherence with the 
programmes. Descriptions of adherence were as overall percentage attendance at sessions 
in 3 papers63, 68, 69 percentage of subjects attending at least a certain proportion of total 
sessions in 3 papers 14, 32, 59 and two papers reported both60, 69. 
 
Reasons for screen failure and poor uptake or adherence 
Screen failures: 
The level of detail in reporting reasons for screen failures was highly variable, with two 
papers accounting for every patient57, 70, whilst several others reported only “screen failure” 
in accounting for patients who were not recruited.  
 
Of the 23 reports specifying total numbers of patients screened, with a cumulative total of 
7517 screened for 1820 patients recruited, there were 5697 screen failures. Of these screen 
failures, 2566 (45%) did not have a reason for screen failure specified (reported only as 
“screen failure” or “other”).  A further 614 patients had a list of reasons for exclusions 
reported but without quantifying the number of patients excluded for each reason.  Thus 
only 2517 screen failures had quantified reasons for non-inclusion and these are shown 
grouped into categories and ranked by frequency in table 2. 
 
10 papers reported uptake of less than 100% with 89 randomised patients failing to 
commence SEP.  Five reports (33 patients) stated only “did not receive intervention” or gave 
no reasons for incomplete uptake. Where reasons were reported, patient withdrawal was 
the most frequent and insurance, exacerbation of co-morbidities or death also reported.  
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Poor adherence: 
Again, reports varied widely in level of detail provided as to reasons for incomplete 
adherence to SEPS. Forty five of the 67 papers with a total of 3518 SEP patients reported 
incomplete adherence amongst 1066 study patients (30.3%). Of these 171 patents (16%) did 
not have a reason for incomplete adherence specified (no reasons given in report or “other 
specified”). A further 71 patients had a list of reasons for incomplete adherence reported 
but without quantifying the number of patients associated with each reason.  Thus only 824 
patients had quantified reasons for incomplete adherence and these are shown grouped 
into categories and ranked by frequency in table three. 
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Discussion 1 
SEPs have been shown to be both clinically and cost effective in treatment of IC and there is 2 
a wealth of evidence supporting the recommendation of SEP as the first line treatment for 3 
IC. However the results of this review suggest that this evidence may not be universally 4 
applicable to the IC population as a whole.    5 
The majority of trials included in this review gave no indication of numbers of IC patients 6 
screened for inclusion which makes the application of their results difficult.  Where 7 
screening information was reported many of the reasons for non-inclusion are not recorded. 8 
For those with reasons for exclusion,  almost 1 in 3 were excluded due to refusal on the part 9 
of the patient (30.6 %).Co-morbidities preventing exercise followed (16.2 %) with inability to 10 
attend classes due to location or timing (11.7 %) preventing a further 1 in 4 from 11 
participating. Clearly the results presented here may include some level of negative bias as 12 
participants were being screened / assessed for inclusion in both a clinical trial as well as an 13 
SEP, potentially reducing the numbers of eligible or amenable recruits. However, 14 
approximately only 1 in every 3 of the screened IC patient population is eligible and willing 15 
to be included in an SEP as part of the included trials. This finding is very similar to results 16 
reported by Muller-Buhl in a prospective observational study who found that only 36% of 17 
their referrals to a SEP for IC were suitable for participation8. Thus the patients studied in 18 
the majority of the included trials, which represent the bulk of the available evidence upon 19 
which current recommendations are based, may therefore represent a better motivated 20 
and less co-morbid cohort within the overall population of IC patients.  21 
 22 
For subjects who were willing and able to participate the rate of uptake once allocated to a 23 
SEP as part of a trial was excellent (98.1%).This may however be an effect of selection bias in 24 
that this group has agreed to participate in SEP in a trial and is likely a subsection of 25 
claudicants with a high level of motivation or willingness to change. Data from our own SEP 26 
(personal communication) and those of Muller-Buhl suggest that as few as 24% of eligible 27 
patients will actually attend SEP sessions despite initially agreeing to participate when 28 
referred.  29 
 30 
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Overall adherence was reported as 75% for those subjects allocated to SEP though very few 31 
reports gave any specific figures for adherence within their study populations. Furthermore 32 
only one defined a target figure for attendance that determined acceptable attendance. It is 33 
very possible that the specifics of the SEP might influence the rate of uptake and adherence.  34 
There was a very wide range of SEPS included in this review (table 1) including aerobic and 35 
resistance training with varied frequencies over markedly different durations. It is also 36 
interesting to note that those trials with the lowest levels of uptake and adherence tended 37 
to be those with longer duration, frequency and reduced variety in the activity performed.  38 
 39 
 40 
Patient lack of motivation was a major reason for screen failure and for poor adherence as 41 
shown in Table 2 and 3.  Improving this willingness to exercise relies on an understanding of 42 
why patients refuse to undertake SEP, which is not available in the included reports. 43 
However vascular patients are often a group who have made certain unhealthy lifestyle 44 
choices and whom are perhaps amongst the least likely patients to embrace an ongoing 45 
commitment to taking responsibility for their own health71. A further point to note is that 46 
current recommendations 7, 72 promote walking to the point of claudication and beyond This 47 
pain may discourage some patients from participating. A review by Parmenter et al 73 has 48 
provided evidence to suggest that clinically relevant improvements in walking distance can 49 
be attained at a lower threshold and without inducing pain. A further review by Al-Jundi et 50 
al 74 also highlights this point concluding that avoidance of painful exercise may lead to 51 
higher participation rates and make it more likely for patients to maintain behavioural 52 
changes in the longer term.   53 
 54 
Co-morbidities were the reason a significant proportion of patients were not enrolled in or 55 
failed to complete SEPs in this review. To highlight this further, death was the third most 56 
frequent reason reported for incomplete adherence to SEP. Some of these patients are 57 
simply unable to exercise to any extent due to arthritis, angina or breathlessness rendering 58 
them entirely unsuitable for SEP. Others may not be referred due to the perception that 59 
systemic cardiovascular disease may make it unsafe for IC patients to undertake exercise. 60 
This was challenged in a systematic review of SEP safety which noted an all-cause 61 
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complication rate of one event per 10,340 patient-hours of SEP 75. However this review was 62 
based upon published trials of SEP (similar to those included in this review, many of which 63 
will have already excluded the more co-morbid patients) and so again may not reflect the 64 
risk for the IC population as a whole.  65 
 66 
Other reasons given for non-inclusion or poor adherence were mainly logistical (travel, 67 
work/family commitment). It may be argued that a way of improving the participation rate 68 
for IC patients would be to promote unsupervised exercise; the old “go home and walk” 76 69 
adage but comparisons of supervised versus unsupervised exercise clearly demonstrates 70 
that this is not an effective treatment strategy. It also has worse adherence rates in 71 
comparison to supervised programmes 6. To counter this there has been a greater interest 72 
in the “home-exercise” programme (HEP) which is potentially more convenient for patients 73 
particularly within the working demographic range.  A systematic review 74 has provided 74 
some evidence that HEP can demonstrate improvements in walking distances and quality of 75 
life in patients with IC. Though the authors conclude that this improvement was still not 76 
equivalent to that achieved by an SEP and, in common with the findings of this review, the 77 
studies included did not clearly present exercise adherence or decline rates 74. Additionally, 78 
the use of personal health-devices such as pedometers or smart phone apps has also had 79 
some beneficial effects in the IC population 25. These can be used in conjunction with a 80 
home-exercise programme to help the clinician monitor the patient’s compliance to the 81 
exercise training. They may also have a motivational effect via visual and quantitative 82 
feedback.  83 
  84 
It remains to be established exactly what might constitute the “ideal” exercise training 85 
programme and indeed there may well be different ideal programmes for clinical 86 
effectiveness and for patient satisfaction, uptake and adherence. Evidence of efficacy for 87 
the patients who have undertaken SEP is compelling and improving the uptake of SEP for 88 
those able to exercise is a significant challenge. Examining the reasons for poor uptake and 89 
or adherence may allow SEP providers with insight as to how to increase participation in 90 
SEP. 91 
 92 
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Conclusions 93 
Details of populations screened, reasons for exclusion and definitions of adequate uptake 94 
and adherence were lacking in the majority of reports. Where data was reported, only  1 in 95 
3 patients screened were suitable for and willing to undertake SEP. This has potential 96 
implications for the recommendation of SEP as first line treatment for all IC patients as 97 
there may be a significant proportion of patients where SEP treatment is not accepted or 98 
possible. Future reports regarding SEP trials need to include full details of screened 99 
populations, and rates of uptake and adherence to exercise. This will ensure more 100 
consistent reporting of data and allow for findings to be interpreted with greater clarity. 101 
 102 
Ultimately the prescription of SEP in the IC population is effective and beneficial but the 103 
results from this review suggest that it is not a “one-size fits all” model. Future research into 104 
the development of more accessible and or acceptable SEPS may improve current uptake 105 
and adherence rates.  106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
 120 
 121 
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